UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average I	burden				
houre por roeponeo	0.5				

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

pe Responses	s)													
Name and Address of Reporting Person Binder-Scholl Gwendolyn Knowlton				2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) 777 SOUTH BROAD STREET, APARTMENT 509				3. Date of Earliest Transaction (Month/Day/Year) 01/12/2018					X	X Officer (give title below) Other (specify below) Chief Technology Officer				
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
	(State)	(Zip)			Та	ble I	- Non-Deriv	ative Securitie	es Acquired	l, Disposed o	of, or Benef	icially Owned		
Security		2. Transaction Date (Month/Day/Year	Execu any	tion	Date, if Co	ode nstr.	(A 8) (In	(A) or Disposed of the str. 3, 4 and 5)	of (D) Own Train	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) For I (I)			Ownership of orm: Direct (D) Or Indirect (Indirect (Indi	Nature Findirect eneficial wnership nstr. 4)
Report on a s	separate line for each	class of securities b	eneficial	lly o	wned direct	ly or	Persons in this fo	orm are not re	equired to	respond u				74 (9-02)
		Table II								ned				
	Conversion Date (Month/Day/Year) Price of Derivative		4. Transaction Code) (Instr. 8)		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			Derivative Securities Beneficially Owned Following Reported	Form of Derivative Security: Direct (D) or Indirect (I)	11. Nature of Indirec Beneficial Ownershij (Instr. 4)
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
	01/12/2018		A		429,984		(2)	01/12/2028	Ordinary Shares	429,984	\$ 0	429,984	D	
\$ 0.0014	01/12/2018		A		96,036		<u>(4)</u>	<u>(5)</u>	Ordinary Shares	96,036	\$ 0	96,036	D	
	d Address of choll Gwe st) OELPHIA, OELPHIA,	choll Gwendolyn Knowlton (Street) DELPHIA, PA 19147 (State) Security Report on a separate line for each 2. Conversion or Exercise Price of Derivative Security \$ 1.3 (1) 01/12/2018	and Address of Reporting Person* choll Gwendolyn Knowlton St) (First) (Middle) JTH BROAD STREET, APARTMENT (Street) DELPHIA, PA 19147 (State) (Zip) Security 2. Transaction Date (Month/Day/Year) Conversion or Exercise Price of Derivative Security \$ 1.3 (1) 01/12/2018	and Address of Reporting Person* choll Gwendolyn Knowlton st) (First) (Middle) JTH BROAD STREET, APARTMENT (Street) 4. If An DELPHIA, PA 19147 (y) (State) (Zip) Security 2. Transaction Date (Month/Day/Year) Report on a separate line for each class of securities beneficia Table II - Deriva (e.g., p.	and Address of Reporting Person* chold Gwendolyn Knowlton st) (First) (Middle) dTH BROAD STREET, APARTMENT (Street) 4. If Amend DELPHIA, PA 19147 (State) (Zip) Gecurity 2. Transaction Date (Month/Day/Year) Report on a separate line for each class of securities beneficially of the Conversion of Exercise Price of Derivative Security 2. Table II - Derivative (e.g., puts, any (Month/Day/Year)) Adaptimm 3. Date of Export of Exercise (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (E.g., puts, any (Month/Day/Year)) 4. Transaction Code (Instr. 8) Code V \$ 1.3 (1) 01/12/2018 A	2. Issuer Name and Ti Adaptimmune Their Adaptimmune Their Adaptimmune Their Adaptimmune Their Adaptimmune Their O1/12/2018 (Street)	and Address of Reporting Person—choll Gwendolyn Knowlton (Street) (A. If Amendment, Date Orige Execution Date, if Code any (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	2. Issuer Name and Ticker or Trading S Adaptimmune Therapeutics PLC Adaptimmune Therapeutics PLC Adaptimmune Therapeutics PLC OLITH BROAD STREET, APARTMENT (Street) (Street) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) A Deemed Execution Date, if any (Month/Day/Year) A Month/Day/Year) 2. Transaction Date (Month/Day/Year) A Deemed Execution Date, if any (Month/Day/Year) A Code (Instr. 8) Persons in this fe a currer Table II - Derivative Securities Acquired, Dispose (e.g., puts, calls, warrants, options, core in this fere a current or Experizion (Month/Day/Year) A Securities Code (Month/Day/Year) A Securities Code (Instr. 3, 4, and 5) Code V (A) (Month/Day Date Experizion (Month/Day A 429,984 (2) \$ 1.3 (1) 01/12/2018 A 429,984 (2)	2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP] 3. Date of Earliest Transaction (Month/Day/Year) 01/12/2018 4. If Amendment, Date Original Filed(Month/Day/Year) 01/12/2018 5. Date of Earliest Transaction (Month/Day/Year) 01/12/2018 4. If Amendment, Date Original Filed(Month/Day/Year) 01/12/2018 5. Tansaction Date (Instr. 8)	Address of Reporting Person* choll Gwendolyn Knowlton (First) (Middle) TTH BROAD STREET, APARTMENT (Street) (A) If Amendment, Date Original Filed(Month/Day/Year) (Code (A) or Disposed of (D) (Instr. 3, 4 and 5) (Instr. 3, 4 and 5) (Instr. 3, 4 and 5) (Instr. 3) (Instr. 3	Address of Reporting Person*- choll Gwendolyn Knowlton Adaptimmune Therapeutics PLC [ADAP] Street) 4. If Amendment, Date Original Filed(Month/Day/Year) O1/12/2018 4. If Amendment, Date Original Filed(Month/Day/Year) O1/12/2018 5. Relationship Director A Officer (give Nominal Poly (State) Code V Amount (A) or Director (Instr. 3, 4 and 5) Code Conversion Date (Month/Day/Year) Conversion Date (Month/Day/Year) A Derivative Securities Code Conversion Date (Month/Day/Year) A Derivative Securities Code (Instr. 8) A 429,984 A 429,984 A 429,984 A 429,984 Coding Transaction Date (Month/Day/Year) Coding Transaction Coding Transaction Coding Transaction Coding Transaction Coding Transaction Coding Transaction Conversion Code Code Code Code Code Code Code Code	Address of Reporting Person hold Gwendolyn Knowlton Adaptimmune Therapeutics PLC [ADAP] (Street) ((Street) (Street) (St	Address of Reporting Person	Address of Reporting Persons* 2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP] (Triss) (Mindle) (M

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Binder-Scholl Gwendolyn Knowlton 777 SOUTH BROAD STREET, APARTMENT 509 PHILADELPHIA, PA 19147			Chief Technology Officer			

Signatures

/s/ Gwendolyn Binder-Scholl	01/17/2018
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise price was converted from GBP0.96 based on an exchange rate of \$U.S. 1.3542 GBP1.00. The actual exercise price will be the pounds sterling amount.
- (2) Exercisable as to 107,496 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 8,958 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022.
- (3) The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of \$U.S. 1.3542 GBP1.00. The actual exercise price will be the pounds sterling amount.
- (4) Exercisable as to 24,009 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 24,009 Ordinary Shares on the twelfth of each January 16, 2020 through January 12, 2020.
- (5) The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.